Posted by Michael Wonder on 15 Aug 2016
ABPI responds to the International Comparisons of Health Technology Assessment report and claims that patients are being denied life-prolonging treatments
15 August 2016 - The Association of the British Pharmaceuticals Industry has responded to the International Comparisons of Health Technology Assessment report, published today, and also addressed claims that patients are being denied life-prolonging treatments for cancer.
The International Comparisons of Health Technology Assessment report published today reviewed the drug systems and the availability of breast and prostate cancer treatments in England, Scotland and Wales compared to five similar countries: Germany, France, Australia, Canada and Sweden.
